Market Research Report: Corealis Pharma Inc.
Company Overview
Company Name: Corealis Pharma Inc.
Mission: Corealis Pharma aims to deliver high-quality formulation development and clinical supplies manufacturing of oral solid dosage forms, facilitating the innovative transition from drug development to commercialization, and providing access to cutting-edge therapies to patients worldwide.
Founded: 2005
Founders: Yves Roy, Patrick Gosselin, and Yves Mouget
Key People: Yves Roy (President)
Headquarters: Laval, Quebec, Canada
Number of Employees: No information is available
Revenue: The company recorded a notable 20% increase in sales for 2023.
Known For: Corealis Pharma is recognized globally as a leading Contract Research and Development Organization (CRO/CDMO) specializing in oral solid dosage formulation development and manufacturing for clinical trials.
Products and Services
Corealis Pharma offers the following key services:
1. Formulation Development Services
- Pre-formulation: Characterization of Active Pharmaceutical Ingredients (APIs) for guiding formulation strategies.
- Formulation: Developing phase-appropriate drug products.
- Analytical Services: Providing analytical method development and validation.
2. Clinical Supply Manufacturing
- Manufacturing and packaging services for pharmaceutical products for clinical trials.
3. Quality Systems and Qualifications
- Ensures compliance with industry regulatory standards across American, Canadian, and European territories.
4. Release and Stability Testing
- Ensures consistency and longevity of drug products.
5. Technical Transfer and Dossier Reports
- Assists in seamless technology transfer and documentation essential for regulatory filings.
Recent Developments
Facility Expansion:
- Inauguration of New Facilities: On June 10, 2024, Corealis inaugurated expanded facilities at Laval Science Park, increasing its space from 33,000 to 63,000 square feet. This $10 million investment enhances its R&D capability and affirms Corealis’ status on a global stage.
- Laboratory Expansion: Completed in March 2024, adding 15,000 sq. ft to its laboratory facilities, allowing more capacity for formulation development, sample preparation, and enhancing analytical equipment.
Recent Strategic Growth Initiatives:
- New Partnerships: Corealis partnered with CDPQ and Archimed, a healthcare-focused investment firm, to further its market reach, especially in New England and California.
- Brand Refresh: Introduced a new brand tagline, “Solid Science,” to better reflect the company's expertise and market presence.
Industry Engagement:
- Key Events and Conferences: Corealis actively participates and sponsors significant industry events such as J.P. Morgan Healthcare Conference, Biocom California event, and DCAT Week. Their presence underscores their commitment to partnerships and industry developments.
Conclusion
Corealis Pharma Inc. continues to fulfill its strategic vision through substantial investments in infrastructure and branding, allowing the firm to maintain its position at the forefront of oral solid dosage form formulations. Despite the lack of information on certain operational metrics (e.g., employee count), the company's recent growth initiatives and partnerships highlight its robust position in the pharmaceutical sector. With an emphasis on timely project delivery and regulatory compliance, Corealis remains a trusted partner for biotech and pharmaceutical industries globally.
